Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.

@article{Weber2005LowdoseOC,
  title={Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.},
  author={Robert Walter Weber and Steven J. O’Day and Madalene Rose and Regina Deck and Patricia Ames and James E. Good and John M. Meyer and R. W. Allen and Sharon Trautvetter and M G Timmerman and Scott Cruickshank and Mary S. Cook and Rene Gonzalez and Lynn E. Spitler},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 35},
  pages={
          8992-9000
        }
}
PURPOSE The objective of this study was to further investigate the efficacy and safety of low-dose outpatient chemobiotherapy in patients with unresectable metastatic melanoma. PATIENTS AND METHODS Thirty-one patients with histologically confirmed unresectable measurable metastatic melanoma were enrolled onto an open-label, multicenter phase II study. The treatment regimen consisted of oral temozolomide followed by subcutaneous biotherapy with granulocyte macrophage colony-stimulating factor… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Temozolomide for Treating Malignant Melanoma.

  • Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • 2015